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Under the umbrella of the Organization for Economic Cooperation and Development (OECD) the rodent 
Hershberger bioassay is being validated as an in vivo screen for the detection of (anti)androgens. As 
part of the validation work we studied trenbolone (TREN), 1,1-bis-(4-chlorophenyl)-2,2-dichloroethylene 
(p,p'-DDE) and vinclozolin (VIN). Oral intubation of castrated rats with TREN [0.3-1.5-8-40 mg kg-1 body 
weight (b.w.)] for ten days increased androgen-sensitive tissue weights (ASTW) at the high dose. p,p'-DDE 
(5-16-50-160 mg kg-1 b.w.) and VIN (0-3-10-30-100 mg kg-1 b.w.) orally administered for ten days produced 
a dose-dependent decrease in ASTW in castrated rats subcutaneously supplemented with testosterone 
propionate (0.4 mg kg-1 b.w.). p,p'-DDE also strongly increased liver weights and induced hepatocellular 
hypertrophy and thyroid follicular cell hypertrophy that was most likely mediated by liver enzyme induction. 
Our data strongly suggest that the OECD protocol of the rodent Hershberger bioassay describes a sensitive 
in vivo screen, capable of detecting weakly active (anti)androgens. Furthermore, our data may also indicate 
that thyroid effects could be assessed, if the protocol is amended accordingly.
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The rodent Hershberger bioassay was first 
described in 1953 by Hershberger and colleagues 
(1) as a screening assay for androgenic and anabolic 
agents. Hershberger et al. used the increase in the 
weight of prostate/seminal vesicles and levator ani 
muscle in castrated rats as indicators of androgenicity 
and anabolic activity, respectively. Since that time, 
the Hershberger bioassay has been used primarily 
by the pharmaceutical industry to screen for strong 
androgens/anabolic agents and - by using a modified 
version employing testosterone-supplemented 
castrated rats - to screen for effective antiandrogens. 
The characterization of various environmental 
chemicals as compounds with androgen- or 
antiandrogen-like activity (2-6) has prompted a need 
for a reliable in vivo screen capable of detecting 
such compounds. The Hershberger bioassay in rats 
was considered as the first choice in this respect; 
however, an internationally accepted assay protocol 
for toxicological purposes was not available. Thus, 
OECD took over the lead to develop and validate a 
robust protocol that can be considered as the basis 
for an OECD Test Guideline.
The current protocol for this study (phase 2) is 
based on the standardisation and optimisation work 
performed under OECD auspices in phase 1 of the 
Hershberger bioassay validation. The assay was robust 
and reproducible across laboratories in the presence of 
several variations, e.g., strain of rat, diet, and modest 
variations in the age of castration. All laboratories and 
all protocols were successful in detecting increases in 
the weights of the accessory sex organs and tissues in 
response to testosterone propionate, and in detecting 
the anti-androgenic effects of flutamide, and there was 
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a good agreement among laboratories with regard 
to the dose responses obtained for testosterone 
propionate and flutamide (7).
The objective of the phase 2 of the validation 
was to further assess the reliability and relevance of 
the assay. Specific aims were to (a) demonstrate the 
reliability of the Hershberger bioassay to respond to 
and to identify additional androgen receptor agonists, 
namely 17α-methyltestosterone and trenbolone 
(TREN) and weak antagonists, namely vinclozolin 
(VIN), procymidone, linuron, and p,p'-DDE using two 
different dose levels of TP to restore androgen sensitive 
tissue weights, (b) to investigate the reproducibility 
of the assay with these additional agonists and 
antagonists, (c) to study the relative effectiveness of 
different sex accessory tissues and glands in the assay, 
(d) to evaluate the capability of the assay to detect the 
5α-reductase inhibitor finasteride through differential 
response of the sex accessory tissues and glands, and 
(e) to investigate whether optional organ weights of 
liver, kidneys and adrenals could contribute to the 
detection of weakly active compounds. Our part in this 
international effort was to conduct studies on TREN,
p,p'-DDE, and VIN according to the OECD protocol. 
In addition to and outside the scope of the OECD 
protocol, we performed histological examination of the 
liver and thyroid of p,p'-DDE-treated rats. The results 
of these studies are described below.
MATERIAL AND METHODS
General
Investigations were performed in compliance with 
good laboratory practice and in agreement to the 
German law of animal experimentation. All parts of the 
study, i.e., study protocol, in-life phase, raw data and 
the study report were subjected to quality assurance 
inspections.
Chemicals
Trenbolone (≥95 %) and corn oil were purchased 
from Sigma (Taufkirchen, Germany), Vinclozolin 
(99.2 %), p,p'-DDE (99.5 %), flutamide (99.9 %) and 
testosterone propionate (97 %) were obtained through 
the OECD Chemical Repository at TNO (Nederlandse 
organisatie voor toegepast-natuurwetenschappelijk 
oenderzoek, Delft, The Netherlands)
Animal treatment
Investigations were performed according to the 
OECD phase 2 protocol (8). Forty day old (breeder´s 
information) SPF-bred male Wistar rats (strain Hsd/
Cpb:WU) were obtained from Harlan-Winkelmann 
(Borchen, Germany) and were maintained under 
controlled conditions. The animal room had a 12 h 
light/dark regime, a temperature of 22±2 °C, relative 
humidity of approximately 55 % and a rate of air 
exchange of ≥10-fold per hour. Animals had free 
access to NAFAG No. 9439 mouse and rat pellet diet 
(supplied by Eberle Nafag AG, Gossau, Switzerland) 
and to drinking water. Five days after their arrival, 
the animals were castrated. Thereafter they were 
acclimatised to laboratory conditions for one week 
until treatment began. Their state of health was also 
monitored during this period. Only healthy animals 
showing no clinical signs were used for the study. One 
day before the treatment began, castrated rats were 
randomly assigned to vehicle and treatment groups 
(n=6 each) in the way that mean body weights were 
similar in all groups. Test compounds were formulated 
in corn oil at the beginning of the study and were 
stored in a refrigerator throughout the study. Except 
for higher concentrations of TREN, clear solutions 
were obtained. Suspensions of TREN were thoroughly 
stirred before administration. Test compounds were 
administered for 10 days using dosing volumes 
of 5 mL kg-1 b.w. for oral and 0.5 mL kg-1 b.w. for 
subcutaneous (s.c.) application. TREN, p,p'-DDE and 
VIN were studied in separate experiments. TREN was 
administered by oral intubation at dose levels of 0.3, 
1.5, 8, and 40 mg kg-1 b.w., whereas control animals 
received only the vehicle. TP (0.4 mg kg-1 b.w., s.c.) 
served as positive control. p,p'-DDE and VIN were 
administered orally at the doses of 5, 16, 50, and 
160 mg kg-1 (p,p'-DDE) and 3, 10, 30, and 100 mg 
kg-1 b.w. (VIN) to castrated rats supplemented with 
TP (0.4 mg kg-1 b.w., s.c.). Orally applied flutamide 
(3 mg kg-1) was used as a reference antiandrogen. In 
addition, a vehicle control group served as a measure 
for maximal weight reduction of androgen-sensitive 
tissues. Animals were inspected for clinical signs at 
least once a day, body weights were recorded daily.
Necropsy
One day after the last treatment, animals were 
killed in deep anaesthesia by exsanguination. Liver, 
kidneys, adrenals, ventral prostate (VP), seminal 
vesicles (SV), glans penis (GP), levator ani and 
bulbocavernosus muscles (LABC), and Cowper's 
glands (CG) were rapidly removed, trimmed free of 
fat and adjacent tissue and weighed.
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Body weight development
No significant effects on food intake were observed 
and final bodyweights of the treated groups were not 
significantly different from those of the castrated 
control group (Table 1). However, body weight gain 
decreased in the group receiving 40 mg kg-1 b.w. of 
TREN and increased in the TP group.
Organ and tissue weights
Liver and kidney weights were unaffected by 
treatment with TREN or TP. In comparison to the 
control group, the absolute and relative adrenal 
weights decreased at doses 0.3 mg kg-1 b.w. of TREN 
and above; the differences were partly statistically 
significant, but not dose-related. Adrenal weights also 
increased in TP-treated animals (Tables 1 and 2).
The high dose of TREN induced an increase in 
absolute and relative weights of prostate, seminal 
vesicles together with coagulating gland, Cowper's 
glands, levator ani and bulbocavernosus muscles, 
Histology
Livers and thyroids from all animals of the study 
with p,p'-DDE (with the exception of the flutamide and 
vehicle control groups) were fixed in a 10 % neutral 
buffered formalin. Paraffin sections were prepared by 
routine techniques, stained with haematoxylin and 
eosin, and examined microscopically.
Statistics
For statistical evaluation, Dunnett's test was used. 
The criterion for significance was set at p≤0.05.
RESULTS
TRENBOLONE STUDY
Appearance, behaviour, and mortality
No clinical signs were observed and no animal died 
throughout the entire treatment period.
Table 1  Effects of orally administered trenbolone (TREN) and subcutaneously administered testosterone propionate (TP) on body, absolute organ 
and tissue weights of castrated rats. Castrated rats were treated either with TREN or TP for ten days. One day after the last administration,
terminal body and organ and tissue weights were recorded.
Treatment N Dose Body weight/g Optional organ weights Androgen-sensitive tissue weights/mg













Vehicle 6 201±15 239±18 10.38±0.95 1.60±0.19 56±8 26±13 63±19 48±4 196±40 5.7±1.9
TREN 6 0.3 203±11 243±11 10.33±0.76 1.52±0.11 46±7 30±16 58±9 48±4 186±37 5.2±1.3
TREN 6 1.5 206±12 248±19 10.67±1.34 1.49±0.12 48±8 32±15 77±16 52±6 219±31 7.3±1.2
TREN 6 8.0 210±9 237±12 10.56±0.87 1.58±0.06 43±7** 29±16 68±31 51±7 224±37 5.5±0.7
TREN 6 40.0 207±16 224±24 10.36±2.26 1.501±0.24 45±6* 48±23 155±72 70±11** 395±51** 11.2±2.4**
TP, s.c. 6 0.4 205±10 259±17 11.01±1.12 1.57±0.12 45±5* 157±31** 744±164** 82±10** 578±38** 30.3±4.5**
N - number of animals; LABC - levator ani and bulbocavernosus muscles. 
Statistical significance: * - p<0.05; ** - p<0.01 (compared to vehicle control).
Table 2  Effects of orally administered trenbolone (TREN) and subcutaneously administered testosterone propionate (TP) on relative organ and 
tissue weights of castrated rats. For experimental details see Table 1. To obtain relative organ and tissue weights, the recorded absolute 
weights were divided by the corresponding body weights (b.w.).
Treatment N Dose Optional organ weights / mg per 100 g b.w. Androgen-sensitive tissue weights / mg per 100 g b.w.







Vehicle 6 4347±193 669±49 23±3 11±6 26±8 20±2 82±15 2.4±0.8
TREN 6 0.3 4240±179 626±30 19±3 12±6 24±4 20±2 76±17 2.2±0.5
TREN 6 1.5 4299±307 601±486 19±3 13±7 31±7 21±2 89±15 3.0±0.6
TREN 6 8 4457±298 670±415 18±4* 12±7 29±13 22±3 94±13 2.3±0.3
TREN 6 40 4582±527 669±67 20±3 21±9* 69±30** 31±4** 177±26** 5.1±1.2**
TP, s.c. 6 0.4 4238±217 606±36 17±1** 61±12** 288±65** 32±5** 223±15** 11.7±2.0**
N - number of animals; LABC - levator ani and bulbocavernosus muscles.
Statistical significance: * - p<0.05; ** - p<0.01 (compared to vehicle control).
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and glans penis. These differences from controls 
were predominantly statistically significant. Similarly, 
TP significantly increased the weights of all these 
androgen sensitive tissues. Whereas 40 mg kg-1 b.
w. TREN and TP were similarly effective in increasing 
the (relative) weights of LABC and glans penis, TP 
was more effective than TREN in Cowper's glands 
and even more effective in the ventral prostate and in 
the seminal vesicles plus coagulating glands (Tables 
1 and 2).
STUDY WITH p,p'-DDE
Appearance, behavior, and mortality
Clinical signs were only observed in TP-
supplemented rats treated with 160 mg kg-1 b.w. 
p,p'-DDE, whose water intake and urine excretion 
increased. No animal died throughout the treatment 
period.
Body weight development
No significant effects on food intake were 
observed. In TP-treated animals, treatment with 
p,p'-DDE or flutamide did not result in a statistically 
significant change in the final body weights. However, 
at the dose of 160 mg kg-1 b.w. of p,p'-DDE, body 
weight gain considerably decreased. As in the study 
with trenbolone, body weight gain in TP-supplemented 
rats was higher than in the castrated control group 
(Table 3).
Organ and tissue weights
Compared to TP-treated animals, enlarged livers 
were observed in DDE-treated animals, whose 
incidence (2-4-6-6 animals per treatment group) 
increased in a dose-dependent manner. Concomitantly, 
an increasing liver weight was observed in p,p'-DDE-
treated animals. This increase was marked, resulting 
in a 50 % liver weight increase at the high dose of 
p,p'-DDE. Liver weights of flutamide-treated and 
castrated control groups were similar to those of the 
TP group. In general, weights of kidneys and adrenals 
were similar for all treatment groups. Only at the high 
dose of p,p'-DDE, relative kidney and adrenal weights 
increased, presumably due to reduced body weight 
(Tables 3 and 4).
Compared to the TP-treated group, p,p'-DDE 
produced a dose-dependent decrease in the weights 
of all investigated androgen-sensitive tissues. Marked 
and predominantly statistically significant weight 
reductions were observed at 50 mg kg-1 b.w. p,p'-DDE 
and above. At the high dose, p,p'-DDE was roughly as 
effective in reducing androgen-sensitive tissue weight 
as the applied dose of flutamide. Neither the high 
dose of p,p'-DDE nor 3 mg kg-1 b.w. flutamide were 
able to decrease androgen-sensitive tissue weight to 
the extent observed in the castrated control group 
(Tables 3 and 4).
Histology
These investigations were performed outside 
the scope of the OECD protocol. No findings 
were observed in the livers of TP-treated animals. 
Histological correlates of the increased liver weights in 
p,p'-DDE-treated animals were a strong hepatocellular 
hypertrophy and cytoplasmic change, the incidence 
and severity of which increased with the dose. 
Furthermore, in p,p'-DDE-treated animals, Kupffer 
cell foci decreased in a dose-dependent manner. 
Table 3  Effects of orally administered p,p'-DDE and flutamide (FLUT) on body, absolute organ and tissue weights of testosterone propionate (TP, 
0.4 mg kg-1 subcutaneously) supplemented castrated rats. Castrated rats were concomitantly treated with TP and p,p'-DDE or flutamide 
for ten days. A vehicle group was tested for comparison. One day after the last administration, terminal body and organ and tissue weights 
were recorded.
Treatment N Dose Body weight/g Optional organ weights Androgen-sensitive tissue weights/mg













TP 6 203±13 259±21 12.21±0.99 1.74±0.11 45±7 153 ±16 539±78 80 ±10 529±84 29.3±5.1
+ DDE 6 5 205±19 261±34 12.93±2.31 1.76±0.26 43±8 156±32 601±134 81±10 498±76 27.4±1.7
+ DDE 6 16 211±17 274±20 15.52±1.516* 1.78±0.20 44±4 147±20 524± 86 76±6 451±28 23.5±4.3*
+ DDE 6 50 206±14 257±22 16.73±2.26** 1.78±0.16 46±4 94±22** 402± 98* 73±8 370±41** 17.3±2.5**
+ DDE 6 160 209±13 229±32 17.97±2.89** 1.68±0.24 51±8 40±23** 128± 54** 54±8** 194±36** 10.7±2.9**
+ FLUT 6 3 209±13 262±18 11.91±1.21 1.77±0.14 50±7 35±13** 146± 46** 68±9 253±34.** 10.7±2.1**
Vehicle only 6 209±17 254±26 11.00±1.64 1.63±0.11 51±12 21±17** 65± 17** 44±11** 175±16** 6.2±1.6**
N - number of animals; LABC - levator ani and bulbocavernosus muscles.
Statistical significance: * - p<0.05; ** - p<0.01 (compared to TP-treated castrated rats).
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Compared to the TP-treated group, animals treated 
with 50 mg kg-1 p,p'-DDE, had a higher incidence of 
mild hypertrophy of the thyroid follicular epithelium 
(Table 5).
Table 5  Histological findings in the liver and thyroid of testosterone 
propionate-supplemented, p,p'-DDE-treated castrated rats. 
For experimental details see Table 3.
Histological
findings
Number of animals with findings/
Number of animals investigated
p,p'-DDE / mg kg-1
0 5 16 50 160
Liver
Hepatocellular 
hypertropy 0/6 0/6 4/6 6/6 6/6
 Grade 1 0/6 0/6 1/6 0/6 0/6
 Grade 2 0/6 0/6 3/6 2/6 0/6
 Grade 3 0/6 0/6 0/6 4/6 3/6
 Grade 4 0/6 0/6 0/6 0/6 3/6
Cytoplasmatic 
change 0/6 4/6 6/6 6/6 5/6
 Grade 1 0/6 4/6 3/6 0/6 0/6
 Grade 2 0/6 0/6 3/6 4/6 0/6
 Grade 3 0/6 0/6 0/6 2/6 3/6
 Grade 4 0/6 0/6 0/6 0/6 2/6
Granuloma 0/6 0/6 0/6 1/6 0/6
 Grade 2 0/6 0/6 0/6 1/6 0/6
Kupffer cell foci 4/6 3/6 2/6 1/6 1/6





1/6 1/6 1/6 4/6 1/6
 Grade 1 1/6 1/6 1/6 4/6 1/6
STUDY WITH VINCLOZOLIN
Appearance, behavior, and mortality
No clinical signs were observed and no animal died 
throughout the treatment period.
Body weight development
No significant effects on food intake were 
observed. In TP-treated animals, treatment with p,p'-
DDE or flutamide did not result in any statistically 
significant change in the final body weight. However, 
mild reductions in body weight gain were observed 
in all VIN groups and, more pronouncedly, in the 
flutamide group. As in the other studies, body weight 
gain in TP-supplemented rats was higher than in the 
castrated control group (Table 6).
Organ and tissue weights
Compared to TP-treated animals, increases 
in relative liver weight and relative adrenal weight 
at doses ≥30 mg kg-1 b.w. of VIN were observed, 
whereas kidney weights remained unchanged in all 
dose groups (Tables 6 and 7).
Compared to the TP-treated group, VIN decreased 
the weights of all investigated androgen-sensitive 
tissues in a dose-dependent manner. Marked 
and predominantly statistically significant weight 
reductions were observed at 30 mg kg-1 b.w. VIN for 
ventral prostate, seminal vesicles and LABC. At the 
high dose of VIN, the weight of all androgen-sensitive 
tissues significantly dropped, but the effect was less 
pronounced than the one induced by flutamide. As 
in the study on p,p'-DDE, the reference antiandrogen 
flutamide at 3 mg kg-1 b.w. was unable to decrease 
Table 4  Effects of orally administered p,p'-DDE and flutamide on relative organ and tissue weights of testosterone propionate-supplemented (TP, 
0.4 mg kg-1 subcutaneously) castrated rats. For experimental details see Table 3. To obtain relative organ and tissue weights, the recorded
absolute weights were divided by the corresponding body weights (b.w.).
Treatment N Dose Optional organ weights / mg per 100 g b.w. Androgen-sensitive tissue weights / mg per 100 g b.w.







TP 6 4707±91 671±17 17±2 59±6 210±40 31±5 203±19 11.2±1.2
   + DDE 6 5 4930±341 672±44 16±1 61±14 231±46 31±2 194±43 10.6±1.2
   + DDE 6 16 5672±343** 650±33 16±1 54±9 192±35 28±3 166±12 8.7±2.0*
   + DDE 6 50 6493±502** 693±29 18±2 37±9 157±38 28±3 144±17** 6.7±0.9**
   + DDE 6 160 7866±573** 735±26* 23±4* 17±9** 55±20** 24±4* 86±16** 4.7±0.9**
   + FLUT 6 3 4537±264 674±40 19±3 13±5** 55±16** 26±3 96±10** 4.1±0.9**
Vehicle only 6 4316±217 642±31 20±4 8±7** 25±8** 17±5** 69±8** 2.4±0.6**
N - number of animals; LABC - levator ani and bulbocavernosus muscles
Statistical significance: * - p<0.05; ** - p<0.01 (compared to TP-treated castrated rats).
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androgen-sensitive tissue weights to the extent 
observed in the castrated control group (Tables 6 
and 7).
DISCUSION
Following the standardisation and optimisation 
of the OECD Hershberger bioassay protocol in the 
validation phase 1, which showed that castrated rats 
robustly and reproducibly responded to testosterone 
propionate (TP) and that the anti-androgenic effects of 
flutamide were sensitively detected in TP-supplemented 
rats, the testing of weak (anti)androgens in phase 2 
was an important part of the validation.
Trenbolone (TREN) acetate has extensively been 
used to promote cattle growth. However, data on 
the androgen receptor binding and transactivating 
properties of TREN have become available only 
recently (5, 9, 10). TREN is a potent androgen and 
anabolic agent in vitro and in vivo after subcutaneous 
application; but about 100 times less active if 
administered orally (5). This points towards a strong 
first-pass metabolism at the17β-hydroxyl group that is 
not protected from metabolic activity by the presence 
of a 17α-methyl or 17α-ethinyl group. In line with the 
expected strong metabolism, weight increase of all 
measured androgen-dependent tissues was detected 
only at the high dose of TREN and, in contrast to 
TP, TREN was unable to increase the body weight 
gain of castrated rats. Compared to the effects of 
TP, the high dose of TREN was most active in levator 
ani and bulbocavernosus muscles (LABC) and the 
glans penis, while it was the least active in the ventral 
prostate and seminal vesicles. These findings are in 
line with previously published data (5) and seem to 
reflect the strong dependency of ventral prostate and 
seminal vesicle growth on 5α-reductase-catalysed 
Table 6  Effects of orally administered vinclozolin (VIN) and flutamide (FLUT) on body, absolute organ and tissue weights of testosterone propionate-
supplemented (TP, 0.4 mg kg-1 subcutaneously) castrated rats. Castrated rats were concomitantly treated with TP and VIN or flutamide for 
ten days. A vehicle group was tested for comparison. One day after the last administration, terminal body and organ and tissue weights
were recorded.
Treatment N Dose Body weight/g Optional organ weights Androgen-sensitive tissue weights / mg














TP 6 250±15 309±18 13.19±1.71 1.90±0.18 49±6 179±25 814±25 91±8 653±81 31.7±4.4
   + VIN 6 3 246±16 301±25 13.00±1.99 1.90±0.18 54±8 183±56 914±151 90±12 700±81 36.4±7.7
   + VIN 6 10 244±14 300±17 12.98±0.916 1.86±0.21 60 ±.8 172±38 764±98 84±3 634±57 33.4±4.0
   + VIN 6 30 241±17 295±17 13.75±0.90 1.89±0.13 63±8 130±23 533±117** 92±11 483±24** 29.8±2.4
   + VIN 6 100 244±15 298±19 13.99±1.39 1.86±0.20 62±14 83±26** 347±50** 74±7** 369±24** 20.7±2.9**
   + FLUT 6 3 240±14 288±18 11.96±1.28 180±0.21 53±4 56±7** 218±72** 67±6** 312±53** 14.9±2.6**
Vehicle only 6 249±14 289±20 11.75±0.85 1.70±0.16 54±10 36±20** 110±24** 56±7** 270±19** 8.3±2.1**
N - number of animals; LABC - levator ani and bulbocavernosus muscles.
Statistical significance: * - p<0.05; ** - p<0.01 (compared to TP-treated castrated rats).
Table 7  Effects of orally administered vinclozolin (VIN) and flutamide on relative organ weights of testosterone propionate-supplemented (TP, 0.4 
mg kg-1 subcutaneously) castrated rats. For experimental details see Table 6. To obtain relative organ and tissue weights, the recorded
absolute weights were divided by the corresponding body weights (b.w.).
Treatment N Dose Optional organ weights/mg per 100 g b.w. Androgen-sensitive tissue weights / mg per 100 g b.w.







TP 6 4256±314 613±30 16±1 58± 10 266±55 29±2 213±38 10.3±1.56
   + VIN 6 3 4309±303 632±37 18±2 61±18 308±65 30±4 235±40 12.2±2.5
   + VIN 6 10 4330±153 618±38 20±2* 57±11 256±35 28±2 212±22 11.2±1.3
   + VIN 6 30 4665±178* 641±31 21±2** 44±7 182±47* 31±4 165±16* 10.1±1.2
   + VIN 6 100 4689±242* 622±38 21±4** 28±10** 118±248** 25±4* 124±11** 7.0±1.1**
   + FLUT 6 3 4150±248 623±58 18±2 19±3** 75±22** 23±2** 108±15** 5.2±0.9**
Vehicle only 6 4070±89 588±43 19±2 12±7** 38± 8** 20±2** 94±12** 2.9±0.7**
N - number of animals; LABC - levator ani and bulbocavernosus muscles.
Statistical significance: * - p<0.05; ** - p<0.01 (compared to TP-treated castrated rats).
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formation of dihydrotestosterone from testosterone, 
a metabolic activation step that is not possible with 
TREN. Accordingly, LABC weight appears to be the 
most sensitive parameter, especially for androgens 
that cannot be activated by 5α-reductase.
The DDT metabolite p,p'-DDE was shown to 
interfere with androgenic signalling at the receptor 
level (3). In androgen receptor (AR) binding studies, 
moderate affinity for AR was observed (3, 9, 10). Like 
p,p'-DDE, vinclozolin (VIN) was demonstrated to 
interfere with androgenic signalling at the receptor 
level (2). VIN itself has little or no affinity for the 
androgen receptor and acts through its metabolites 
(2, 9, 10). Both compounds decreased androgen 
sensitive tissue weight even at lower doses, p,p'-
DDE typically at 50 mg kg-1 and above, and VIN at 
30 mg kg-1 and above. Not all tissues responded 
equally. Based on relative weight changes, most 
sensitive tissues were again LABC and Cowper's 
gland for p,p'-DDE and LABC and seminal vesicles 
for VIN. The clear effect of VIN indicates the efficient 
formation of active metabolites. In two independent 
experiments, the reference antiandrogen flutamide 
effectively decreased androgen sensitive tissue weight 
to the same extent, providing further evidence of the 
robustness of the protocol.
Another important aspect of the validation phase 2 
was to compare the sensitivity of the assay when using 
a lower (0.2 mg kg-1) dose of TP to restore androgen 
sensitive tissue weight. In theory, using the lower dose 
should allow compounds with affinity for the androgen 
receptor to more readily displace (dihydro)testosterone 
from its receptor. On the other hand, in the presence 
of the lower dose of TP, androgen sensitive tissues 
would be smaller and trimming would be more 
difficult. A comparison of our data for p,p'-DDE and 
vinclozolin with the published data on validation using 
0.2 mg kg-1 TP (11) does not suggest differences in 
sensitivity between the two approaches.
Finally, the contribution of optional organ weight 
detection and characterisation has to be considered. 
In line with the findings of the validation phase 1, TP 
slightly decreased adrenal weights in castrated rats. 
A comparable change was observed for TREN, but 
without any dose dependency. The massive increase 
in the liver weight of p,p'-DDE-treated animals 
reflected the known and strong liver enzyme-inducing 
properties of this organochlorine compound (12, 13), 
whereas the increased relative kidney weight in high-
dose animals corresponded to the reduced final body 
weight. The high dose of p,p'-DDE, like flutamide, 
increased adrenal weights in TP-supplemented rats to 
the level observed in vehicle controls, but the effect 
was not significant. On the other hand, VIN increased 
adrenal weights beyond the level of flutamide-treated 
and vehicle control rats, but only slightly affected 
liver weights. These findings suggest that potentially 
specific changes in adrenal weight seem to be small 
and eventually superimposed by other effects, and 
that, in general, optional organ weight greatly reflect 
substance-specific findings and thus cannot contribute 
to a sensitive and specific detection of compounds 
with affinity for the androgen receptor.
Histological examination of the liver and thyroid 
of p,p'-DDE-treated animals was performed outside 
the scope of the OECD protocol. In line with 
massive liver weight increase, strong hepatocellular 
hypertrophy was diagnosed, corroborating thus the 
known liver enzyme-inducing properties of p,p'-DDE. 
The observed thyroid follicular cell hypertrophy in 
animals treated with 50 mg kg-1 p,p'-DDE is thus 
considered a secondary effect due to increased 
metabolic disposition of thyroid hormones as the 
consequence of liver enzyme induction (14). Yamada 
et al. (15) reported similar effects for both liver enzyme 
inducers phenobarbital and p,p'-DDE on rat thyroid 
under conditions of Hershberger assay. Surprisingly, 
at the high dose of p,p'-DDE, we did not observe 
thyroid follicular cell hypertrophy. This phenomenon 
remains to be explained. One may speculate that the 
initial toxic effect of the highest-dose p,p'-DDE may 
have hampered necessary induction of the relevant 
liver enzyme glucuronyltransferase.
CONCLUSIONS
Our data suggest that the Hershberger bioassay 
performed in accordance with the OECD protocol 
is a suitable in vivo screen for compounds with the 
affinity for the androgen receptor: Even weakly active 
compounds - such as orally administered TREN, 
moderate androgen receptor antagonist p,p'-DDE and 
VIN, a compound requiring metabolic activation - were 
readily detected. LABC weight was always among 
the most sensitive parameters in these studies. Our 
data also confirm recent findings demonstrating the 
Wistar rat to be a sensitive rat strain for this assay [16]. 
Further testing with 17α-methyltestosterone, linuron, 
procymidone and finasteride and coded testing of 
reference compounds on an international scale will 
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provide comprehensive information on the properties 
of the rodent Hershberger bioassay. Furthermore, 
our data may also indicate that thyroid effects could 
be assessed, if the Hershberger bioassay protocol is 
amended accordingly.
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Sažetak
EVALUACIJA HERSHBERGOVA BIOTESTA NA GLODAVCIMA S POMOÆU TRI REFERENTNA 
(ANTI) ANDROGENA
Hershbergerov biotest na glodavcima potvrðen je u sklopu OECD-ove meðunarodne studije kao in vivo test 
probira za otkrivanje tvari s afinitetom za androgene receptore. Našem laboratoriju povjereno je provoðenje 
istraživanja s anabolièkim agensom trenbolonom (TREN) te s 1,1-bis-(4-klorfenil)-2,2-dikloretilenom 
(p,p'-DDE) i vinklozolinom (VIN). Samo visoka doza TREN primijenjena na kastriranim štakorima oralnom 
intubacijom [0,3 - 1,5 - 8 - 40 mg kg-1 tjelesne mase (t. m.)] tijekom deset dana, jako poveæava masu 
tkiva osjetljivih na androgen. Oralno primijenjeni p,p'-DDE (5 - 16 - 50 - 160 mg kg-1 t. m.) i VIN (0 - 3 
- 10 - 30 - 100 mg kg-1 t. m.) tijekom deset dana u štakora koji su dodatno primali testosteron propionat 
(0,4 mg kg-1 t. m., sc.), izazvali su ovisno o dozi smanjenje težine svih tkiva osjetljivih na androgen. Uz 
to je p,p'-DDE, takoðer ovisno o dozi, izazvao izrazito poveæanje težine jetre i hipertrofiju stanica jetre i 
folikularnih stanica štitnjaèe, što je najvjerojatnije posljedica indukcije enzima jetre. Podaci u radu pokazuju 
da je opisani protokol osjetljiv za probir in vivo te sposoban za otkrivanje slabih (anti)androgena. Nadalje, 
podaci takoðer upuæuju na to da bi se mogli procjenjivati i uèinci na štitnjaèu ako se ovaj protokol prikladno 
unaprijedi.
KLJUÈNE RIJEÈI: metoda probira in vivo, OECD, p,p'-DDE, štitnjaèa, trenbolon, vinclozolin
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